Dr. Reddys launches Levalbuterol Inhalation Solution

24 Sep 2014 Evaluate

Dr. Reddys Laboratories has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).

The XOPENEX (levalbuterol hydrochloride) inhalation solution brand and generic combined had U.S. sales of around $269.7 Million MAT for the most recent twelve months ending in June 2014.

The company's Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg /3 mL are available in Unit-Dose Vials of (5 x 3 mL) carton of 25. Levalbuterol Inhalation Solution, USP is only for use with a nebulizer.

Dr. Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

 

Dr. Reddys Lab Share Price

1283.85 4.95 (0.39%)
22-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1771.25
Dr. Reddys Lab 1283.85
Cipla 1512.50
Zydus Lifesciences 918.20
Lupin 2126.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×